Kanta Devi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kanta Devi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Natasha Ali
Aga Khan University, Karachi, Pakistan
2 shared publications - Arsalan Ahmed
Department of Pathology and Laboratory Medicine, Aga Khan University Hospital, Karachi, Pakistan
1 shared publication Maria Khan
Medical College, Aga Khan University Karachi, Pakistan
1 shared publicationMuhammad Usman Shaikh
Department of Pathology and Laboratory Medicine, Aga Khan University Hospital Karachi, Pakistan
1 shared publicationNatasha Bahadur Ali
Department of Pathology and Laboratory Medicine, Aga Khan University Hospital Karachi, Pakistan
1 shared publicationSalman Muhammad Soomar
Medical College, Aga Khan University Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 29 November 2021
- Published by Elsevier in Leukemia Research Reports
- Vol. 16, 100284
Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
- 29 November 2021
- Published by Elsevier in Leukemia Research Reports
- Vol. 16, 100284
Open AccessOutcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.
- Open Access
- 25 November 2021
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2021 (11-12) , 447-449
Case report of primary CD20 negative diffuse large B-cell lymphoma
Few groups of aggressive non-Hodgkin’s lymphomas (NHL) that are refractory to standard chemotherapy are rarely reported. Primary CD20 negative diffuse large B cell lymphoma (DLBCL) without human immunodeficiency virus infection is an uncommon presentation and this case report is challenging in terms of diagnosis and treatment as well.
- 25 November 2021
- Published by Oxford University Press (OUP) in Oxford Medical Case Reports
- Vol. 2021 (11-12) , 447-449
Open AccessCase report of primary CD20 negative diffuse large B-cell lymphoma
Few groups of aggressive non-Hodgkin’s lymphomas (NHL) that are refractory to standard chemotherapy are rarely reported. Primary CD20 negative diffuse large B cell lymphoma (DLBCL) without human immunodeficiency virus infection is an uncommon presentation and this case report is challenging in terms of diagnosis and treatment as well.